IBM CEO: Watson Health is ‘Our Moonshot’ in Healthcare
By Greg Slabodkin,
Health Data Management
| 04. 20. 2015
Untitled Document
A new IBM business unit launched last week to help physicians, researchers, insurers and patients use big data, analytics and mobile technology to achieve better health outcomes is being described by the company’s chief executive officer as their “moonshot” in healthcare.
“If you go back in time, we have participated in some of the most glorious moments of history, whether it might have been the first systems that ever did census and landing a man on the moon,” said Ginni Rometty, chairman and CEO of IBM, on PBS’s Charlie Rose talk show. “I’m telling you our moonshot will be the impact we will have on healthcare. It has already started. We will do our part to change the face of healthcare. I am absolutely positive about it.”
Last week, IBM announced a new business unit—Watson Health—that will offer cloud-based access to its Watson supercomputer for analyzing healthcare data. Big Blue has partnered with Apple, Johnson & Johnson and Medtronic to make it easier for healthcare organizations to store and analyze patient data by leveraging Watson’s cognitive capabilities and...
Related Articles
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...
By Staff, ScienceDaily | 01.05.2026
Scientists at UNSW Sydney have developed a new form of CRISPR technology that could make gene therapy safer while also resolving a decades-long debate about how genes are switched off. The research shows that small chemical markers attached to DNA
...
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
